Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Revenue projections:

With Bristol-Myers Squibb Company's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio	1.532000
forwardPE	9.035903
debtToEquity	201.859000
earningsGrowth	1.531000
revenueGrowth	0.057000
grossMargins	0.716610
operatingMargins	0.344180
trailingEps	4.540000
forwardEps	6.612510

BMY's current ratio of 1.532 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that BMY is financially well-prepared to meet its liabilities without difficulty.
BMY's elevated debt-to-equity ratio suggests the company is highly leveraged, meaning it has significant debt compared to equity. This can be risky, particularly if BMY's cash flow or profits decrease, making it harder to meet debt obligations.
With positive gross and operating margins, BMY's profitability is evident. These metrics suggest the company is efficiently managing its expenses while maintaining strong revenue, highlighting a solid financial foundation.
Bristol-Myers Squibb Company's forward EPS is higher than its trailing EPS, suggesting the company is expected to see an increase in profitability this year. This points to positive growth, indicating that Bristol-Myers Squibb Company is projected to improve its financial performance compared to the previous year.

Price projections:

BMY's stock price has consistently been near the lower edge of expected values, indicating potential struggles in meeting growth projections. This trend may reflect a cautious market sentiment toward the company.

Insider Transactions:

In recent market activity, 4 sales of BMY shares took place, with market price at 60.36750030517578.There were no sell transactions throughout the period under consideration.The recent trend of increased buying at BMY's current price levels may indicate a favorable market sentiment. This could point to a positive outlook for the stock, as investors show growing confidence through higher buy activity.

Recommendation changes over time:

A recent buy bias from analysts toward Bristol-Myers Squibb Company may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that Bristol-Myers Squibb Company might be an appealing option for those looking to grow their wealth through stock market investments.